Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ethinyl estradiol
Drug ID BADD_D00844
Description Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability.[A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.[A191107] Ethinylestradiol was granted FDA approval on 25 June 1943.[L11884]
Indications and Usage For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
Marketing Status Prescription; Discontinued
ATC Code G03CA01; L02AA03
DrugBank ID DB00977
KEGG ID D00554
MeSH ID D004997
PubChem ID 5991
TTD Drug ID D06NXY
NDC Product Code 65089-0044; 12860-0463; 60870-0463; 63190-0620; 44132-002; 51927-1856; 22552-0034; 44132-010
Synonyms Ethinyl Estradiol | Estradiol, Ethinyl | Ethynyl Estradiol | Estradiol, Ethynyl | Ethinyloestradiol | 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)- | Ethinyl Estradiol Hemihydrate | Hemihydrate, Ethinyl Estradiol | Ethinyl Estradiol, (8 alpha)-Isomer | Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer | Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer | Progynon C | Microfollin | Microfollin Forte | Ethinyl-Oestradiol Effik | Ethinyl Oestradiol Effik | Ethinylestradiol Jenapharm | Jenapharm, Ethinylestradiol | Lynoral | Estinyl | Ethinyl Estradiol, (9 beta,17 alpha)-Isomer
Chemical Information
Molecular Formula C20H24O2
CAS Registry Number 57-63-6
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Acne23.02.01.001--Not Available
Alopecia23.02.02.001--
Amenorrhoea05.05.01.002; 21.01.02.001--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Benign hepatic neoplasm09.04.01.001; 16.06.01.001--Not Available
Breast discharge21.05.05.001--Not Available
Breast enlargement21.05.04.001--Not Available
Breast tenderness21.05.05.004--Not Available
Budd-Chiari syndrome09.01.06.001; 24.01.03.001--
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cataract06.06.01.001--
Cerebral haemorrhage17.08.01.003; 24.07.04.001--Not Available
Cerebral thrombosis17.08.01.006; 24.01.04.003--Not Available
Cervical discharge21.06.01.001--Not Available
Uterine cervical erosion21.06.01.006--Not Available
Chloasma18.08.02.002; 23.05.01.001--Not Available
Colitis07.08.01.001--
Contact lens intolerance06.01.01.003--Not Available
Depression19.15.01.001--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Embolism arterial24.01.01.014--
Erythema multiforme10.01.03.015; 23.03.01.003--
Erythema nodosum10.02.01.020; 23.07.02.001--Not Available
Gallbladder disorder09.03.02.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Haemolytic uraemic syndrome01.06.02.001; 20.01.03.011--
Headache17.14.01.001--
Hepatic adenoma09.04.01.002; 16.06.01.002--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene